Filing Flows › Pure Bioscience (PURE) › Q4 FY26
Pure Bioscience (PURE) Q4 FY26 earnings results (fourth quarter fiscal 2026)
10-K filed Oct 29, 2026
Pure Bioscience (PURE) reported revenue of $659K for the fourth quarter fiscal 2026 (Q4 FY26), -14% from a year earlier and +30% from the quarter before. Operating margin was -76.3%, net loss $610K (92.6% of revenue).
Pure Bioscience, Q4 FY26: revenue $659K (-14% year over year), operating margin -76.3%, net loss $610K, operating cash flow −$414K. The chart follows the revenue to costs, profit and cash.
| Q4 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $659K | +30% | -14% |
| Operating profit | −$503K | — | — |
| Net earnings | −$610K | — | — |
| Operating cash flow | −$414K | — | — |
What changed
Revenue was $659K in Q4 FY26, down 14% year over year and up 30% from the previous quarter. PURE Hard Surface was the largest line at 96% of revenue.
Gross margin was 56.0%, down 5.3 points from Q4 FY25. Operating costs exceeded revenue by $503K, an operating margin of -76.3%. Operating expenses grew 8% against a revenue fall of 14%. The fastest-growing cost line was Research & development (+27%). The quarter ended with a net loss of $610K, narrower than the previous quarter's $624K loss.
Operating cash flow was −$414K. Non-cash charges added back $1K of depreciation and $50K of share-based compensation. Working capital and other items added $145K.
Questions
What was Pure Bioscience's revenue in the fourth quarter fiscal 2026?
Pure Bioscience (PURE) reported revenue of $659K for the fourth quarter fiscal 2026 (Q4 FY26), -14% from a year earlier and +30% from the quarter before.
Was Pure Bioscience profitable in the fourth quarter fiscal 2026?
Operating loss was $503K (-76.3% of revenue) and net loss $610K.
Source: Pure Bioscience 10-K on SEC EDGAR.